EMB-09

N/A

Report date: 2026/05/07 20:00:36

Base Information

Drug NameEMB-09
Drug Alias NameEMB-09
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Bispecific monoclonal antibody
Mechanisms of ActionProgrammed death-ligand 1 blockersTumor necrosis factor receptor superfamily member 4 agonists
TargetsProgrammed death-ligand 1Tumor necrosis factor receptor superfamily member 4
Therapy Area/IndicationsSolid tumoursEndometrial NeoplasmsSmall Cell Lung Carcinoma +[15] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryAustraliaMainland China
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesShanghai Epimab Biotherapeutics, Inc
China Registration ClassClass 1 therapeutic biologic in China

Develop Information

Active CompaniesEpimab Biotherapeutics IncShanghai Epimab Biotherapeutics, Inc
Inactive CompaniesN/A
Active IndicationsSolid tumoursHepatitis B, Chronic
Inactive IndicationsEndometrial NeoplasmsSmall Cell Lung CarcinomaCarcinoma, Non-Small-Cell Lung +[13] 

Other Information

ATC CodeN/A
Related LinksN/A